FAQ/Help |
Calendar |
Search |
Today's Posts |
|
Parkinson's Disease Clinical Trials For posting and discussion of clinical trials related to Parkinson's Disease, and for the Parkinson Pipeline Project. All are welcome. |
Reply |
|
Thread Tools | Display Modes |
08-05-2011, 07:28 AM | #1 | ||
|
|||
Member
|
Oxford BioMedica Announces Interim Data from Highest (5x) Dose Cohort in ProSavin Phase I/II Study in Parkinson's Disease
04 Aug 2011 -- Positive interim review of fourth patient cohort by Data Monitoring Committee -- Oxford, UK | August 4, 2011 | Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces positive interim data from the on-going Phase I/II trial of ProSavin® for the treatment of Parkinson’s disease (PD). The first three patients in the current six-patient cohort were treated with a 5x dose of ProSavin®, the scaled equivalent to the maximum dose in pre-clinical studies, and have reached their three-month assessment. Highlights of fourth patient cohort at three months (n=3, 5x dose) Favourable safety profile with no serious adverse events related to ProSavin® or its method of administration; Data Monitoring Committee (DMC) supports current planning for randomised studies; Highest average motor function¹ improvement of 29% at this time point, with a maximum of 49% improvement in one patient; and Reduction in average daily dose of L-DOPA "equivalent" therapy. |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
ProSavin phase I/II study in Parkinson's disease | Parkinson's Disease | |||
ND0611, a new patch for the treatment of Parkinson's disease | Parkinson's Disease | |||
Hope For New Parkinson's Disease Treatment Through RXR Activation | Parkinson's Disease | |||
Treatment Modalities for Parkinson's Disease | Parkinson's Disease | |||
New pharmacologic horizons in the treatment of Parkinson disease. | Parkinson's Disease |